Omalizumab Therapeutic Cheat Sheet
Chronic idiopathic urticaria is urticaria for greater than 6 weeks without an identifiable trigger. Cases relapse in 20% of patients for more than 5 years and be difficult to manage; however, omalizumab is a recently approved option for treatment of chronic idiopathic urticaria showing beneficial outcomes.1 Omalizumab is an injectable monoclonal antibody that has been FDA approved not just for chr …
Chronic idiopathic urticaria is urticaria for greater than 6 weeks without an identifiable trigger. Cases relapse in 20% of patients for more than 5 years and be difficult to manage; however, omalizumab is a recently approved option for treatment of chronic idiopathic urticaria showing beneficial outcomes.1 Omalizumab is an injectable monoclonal antibody that has been FDA approved not just for chr … 
The September issue of the Journal of Drugs in Dermatology (JDD) focuses on aesthetic treatments and features original articles exploring topics such as reconstruction of the glabella and nasal root, perioral rejuvenation with high molecular weight HA and amino acid treatment, blue light and skin health, and many more. Check out this month’s issue highlights straight from the JDD Editor’s d … 
The August issue of the Journal of Drugs in Dermatology (JDD) focuses on Psoriasis and features mix of original articles, editorials, and case reports. Among many of the topics explored in this issue are treatment of scalp psoriasis, nail psoriasis, respiratory tract infections in patients using biologics for hidradenitis suppurativa, classification of actinic keratosis, lichen planus pigmentosus … 
The February 2022 issue of the Journal of Drugs in Dermatology (JDD) includes the perfect blend of original articles, case reports, and editorials. With topics ranging from psoriasis and actinic keratoses to artificial intelligence in dermatology and disparities in telemedicine satisfaction, we share this month’s issue highlights straight from the JDD Editor’s desk:
Early Response is Associ … 
On this Mnemonic Monday, we challenge you to remember the list of subepidermal and pauci-inflammatory disorders in dermatopathology:
Porphyria cutanea tarda (PCT)
Epidermolysis bullousa acquisita (EBA)
Toxic epidermal necrolysis/Stevens-Johnson syndrome (TEN/SJS)
Bullous pemphigoid
Cicatricial pemphigoid
Dermatitis herpetiformis
Bullous lupus erythematosus (think “SLE”)
Linear IgA bu … 